Abstract
Objective
Although coronavirus disease-2019 (COVID-19) primarily affects the respiratory system, it can also affect other systems. Cardiovascular effects in COVID-19 disease are common in hospitalized patients, and it has been shown that myocardial damage, pericarditis and pericardial effusion (PE) may develop. In our study, we aimed to evaluate the frequency and clinical significance of PE that may develop secondary to COVID-19 infection.
Material and Methods
Thoracic computed tomography images of 989 consecutive COVID-19 patients, who remained after assessing the exclusion criteria, were evaluated. The presence of patients’ non-physiological PE was examined by a radiologist blinded to the study data. The patients were divided into two groups as those with and without PE. The presence of myocardial injury was defined according to hs-TnI levels (≥34 ng/dL).
Results
PE was observed in 125 patients (12.6%). Sixty-three (50.4%) of the patients with PE were female, and there was no difference in terms of PE between the genders (p=0.315). The mean age of patients with PE was 72.8±14.3 years, while it was 64.8±14.9 years in patients without effusion (p<0.001). The frequency of myocardial injury was found to be higher in the group with PE (33.6% vs. 21.4%, p=0.023). In the group with PE (pulmonary embolism), the mortality rate was 36%, while it was 25% in the group without PE (p=0.009). In the group of patients who experienced mortality, age >65, male gender, hypertension, chronic obstructive pulmonary disease, chronic kidney failure, coronary artery disease, heart failure, atrial fibrillation, severe lung parenchymal involvement on CT, and presence of myocardial injury were observed at higher rates (all p-values <0.05).
Conclusion
The presence of PE in hospitalized COVID-19 patients may develop due to either a systemic inflammatory response or direct myocardial injury. Mortality was observed more frequently in this patient group. The presence of PE can be used as a mortality risk predictor in COVID-19 patents, so its routine evaluation in tomography is recommended.
Keywords: Coronavirus, COVID-19 infection, pericardial effusion, computed tomography
References
Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu.https://covid19.saglik.gov.tr/. Erişim tarihi: 08 Nisan 2022.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Furqan MM, Verma BR, Cremer PC, Imazio M, Klein AL. Pericardial Diseases in COVID19: a Contemporary Review. Curr Cardiol Rep. 2021; 23(7):90.
Miró Ò, Llorens P, Jiménez S, Piñera P, Burillo-Putze G, Martín A, et al. Frequency of five unusual presentations in patients with COVID-19: results of the UMC-19-S1. Epidemiol Infect. 2020;148:e189.
Bucher AM, Henzel K, Meyer HJ, Ehrengut C, Müller L, Schramm D, et al. Pericardial Effusion Predicts Clinical Outcomes in Patients with COVID-19: A Nationwide Multicenter Study. Acad Radiol. 2024;31(5):1784-1791.
Saraç İ, Aydın SŞ, Özmen M, Doru Hİ, Tonkaz G, Çırçır MN, et al. Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19. J Cardiovasc Dev Dis. 2023;10(9):368.
Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265-1273.
Diaz-Arocutipa C, Saucedo-Chinchay J, Imazio M. Pericarditis in patients with COVID-19: a systematic review. J Cardiovasc Med (Hagerstown). 2021; 22(9):693-700.
Kermani-Alghoraishi M, Pouramini A, Kafi F, Khosravi A. Coronavirus Disease 2019 (COVID-19) and Severe Pericardial Effusion: From Pathogenesis to Management: A Case Report Based Systematic Review. Curr Probl Cardiol. 2022;47(2):100933.
Abate SM, Mantefardo B, Nega S, Chekole YA, Basu B, Ali SA, et al. Global burden of acute myocardial injury associated with COVID-19: A systematic review, meta-analysis, and meta-regression. Ann Med Surg (Lond). 2021;68:102594.
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-25.
Özer S, Bulut E, Özyıldız AG, Peker M, Turan OE. Myocardial injury in COVID-19 patients is associated with the thickness of epicardial adipose tissue. Kardiologiia. 2021;61(8):48-53.
Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, Cao G. Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020;7:301.
Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020;92(11):2409-2411.
Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci. 2020;7:157.
